hylander - that is the problem with what they actu
Post# of 36563
(Total Views: 344)
Posted On: 09/01/2021 9:09:23 PM
hylander - that is the problem with what they actually say versus what they appear to say. The exact language of the 8-K is:
"On July 22, 2021, Generex Biotechnology Corporation (“Generex”) on behalf of itself and its subsidiary NuGenerex Immuno-Oncology, Inc. (collectively “Generex”) entered into a Quality Agreement with PPD Development, L.P. (“PPD”) regarding Generex’s efforts to develop Generex’s li- Key-SARS-CoV-2 coronavirus peptide vaccine (the “Quality Agreement”). The Quality Agreement describes the standards, expectations, and responsibilities of Generex and PPD with respect to managing quality, including, but not limited to, quality assurance (QA) and quality risk management (QRM) for the services and/or deliverables."
Most people would read it the same way you did, i.e., that PPD and GNBT agreed to do something together. What it really said was that they reached an agreement "regarding" and "with respect to" - in other words, it's an agreement about something, not an agreement to do something.PPD agreed with Generex about GNBT's efforts, and not that PPD actually was providing QA/QC/QRM. It's smoke and mirrors - the agreement is meaningless unless and until GNBT actually puts a vaccine in PPD's hands so that they can manage the quality control aspect of the production.
I don't think that will ever happen, though, because GNBT has not provided any actual evidence that they have produced a COVID vaccine.Moscato has talked about lots of things, but not once has any third party entity said - I have seen this, looked at it, and it in fact is a vaccine. Talk is cheap, unless you're one of the shareholders...
"On July 22, 2021, Generex Biotechnology Corporation (“Generex”) on behalf of itself and its subsidiary NuGenerex Immuno-Oncology, Inc. (collectively “Generex”) entered into a Quality Agreement with PPD Development, L.P. (“PPD”) regarding Generex’s efforts to develop Generex’s li- Key-SARS-CoV-2 coronavirus peptide vaccine (the “Quality Agreement”). The Quality Agreement describes the standards, expectations, and responsibilities of Generex and PPD with respect to managing quality, including, but not limited to, quality assurance (QA) and quality risk management (QRM) for the services and/or deliverables."
Most people would read it the same way you did, i.e., that PPD and GNBT agreed to do something together. What it really said was that they reached an agreement "regarding" and "with respect to" - in other words, it's an agreement about something, not an agreement to do something.PPD agreed with Generex about GNBT's efforts, and not that PPD actually was providing QA/QC/QRM. It's smoke and mirrors - the agreement is meaningless unless and until GNBT actually puts a vaccine in PPD's hands so that they can manage the quality control aspect of the production.
I don't think that will ever happen, though, because GNBT has not provided any actual evidence that they have produced a COVID vaccine.Moscato has talked about lots of things, but not once has any third party entity said - I have seen this, looked at it, and it in fact is a vaccine. Talk is cheap, unless you're one of the shareholders...
(1)
(0)